Highlights

Pr Martin Landray: 1st CETP inhibitor with a proof of efficacy (REVEAL trial) Pr Paul Ridker: lowering inflammation reduces cardiovascular risk ASCO 2017: Cancer de vessie, quelle place potentielle pour l’immunothérapie ? ASCO 2017 :Cancer du sein RH+/R2- métastasé hormono-résistant : quelle chimiothérapie ? Best of ASCO 2016 – Part 2 Best of ASCO 2016 – Part 1 EASD 2015 - An SGLT-2 antagonist reduces mortality in type 2 diabetes

Pr Martin Landray: 1st CETP inhibitor with a proof of efficacy (REVEAL trial)

Today we’ll be devoting our program to the interest of a CETP inhibitor on top of intensive statin therapy At the 2017 European Society of Cardiology meeting, which took place in Barcelona, ...

Pr Paul Ridker: lowering inflammation reduces cardiovascular risk

Today we’ll be devoting our program to lowering inflammation as a way to reduce cardiovascular risk in vertain patients At the 2017 European Society of Cardiology meeting, which took place i...

ASCO 2017: Cancer de vessie, quelle place potentielle pour l’immunothérapie ?

Le cancer de la vessie a bénéficié depuis 2014 de l’arrivée des inhibiteurs du PD1/PDL1. L’ASCO 2017 a été l’occasion de revenir sur l’intérêt et la place de l’immun...

ASCO 2017 :Cancer du sein RH+/R2- métastasé hormono-résistant : quelle chimiothérapie ?

Le cancer du sein RH+/R2- bénéficie de l’hormonothérapie mais, lorsqu’il devient résistant, la stratégie est moins bien définie. Dans ce cas de figure, les objectifs du traitement dictent le choix...

Best of ASCO 2016 – Part 2

James R. Perry, Toronto A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma   Arjun V. Balar, New York Atezolizumab (atezo) as first...

Best of ASCO 2016 – Part 1

John P. Neoptolemos, Liverpool ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with r...

EASD 2015 - An SGLT-2 antagonist reduces mortality in type 2 diabetes

Empagliflozine, an SGLT-2 antagonist, on top of the classic treatment of type 2 diabetes patients at high risk is associated with a reduction in the HbA1c level and the cardiovascular and total mortality....

RSS
Twitter
Facebook
Timeline
Partnership

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
Url
Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
with
Danone Institute International